Clinical Trial Update: Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial reports results on transitioning patients from injectable prostacyclin therapy to inhaled prostacyclin therapy for pulmonary arterial h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Epoprostenol (injectable prostacyclin) (epoprostenol)
• Iloprost (inhaled prostacyclin) (iloprost)

Snippet

Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Conditions: Pulmonary Arterial Hypertension | Phase 4 | Status: COMPLETED | Results posted: 2017-09-01